J Clin Obstet Gynecol Infertil | Volume 1, Issue 1 | Research Article | Open Access

Total Laparoscopic Treatment of Endometrial Cancer – Pilot Study with a New Model of Uterine Manipulator: Operating Data and Five Years Follow-up in a Reference Center in Southern Brazil

Geraldo Gastal Gomes-Da-Silveira1, Cristiane Cruz Nervo1, Mila Pontremoli Salcedo1,2 and Patrícia El Beitune2*

1Service of Gynecology, Complexo Hospitalar Santa Casa de Porto Alegre (ISCMPA), Brazil
2Department of Obstetrics and Gynecology and Post-Graduate Program, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Brazil

*Correspondance to: PatrĂ­cia El Beitune 

Fulltext PDF

Abstract

To evaluate operating data, disease-free (DFS) and overall survival (OS) for women with cancer clinically restricted to the uterine corpus underwent to laparoscopy and the effects of the Gomes-daSilveira manipulator on surgical time and intraoperative complications, sixteen patients treated for endometrial cancer with laparoscopy and followed up for at least 5 years were divided into 2 groups. Group 1, no uterine manipulator; Group 2, with the Gomes-da-Silveira manipulator used during surgery. Mean follow-up was 75 months. Surgery time ranged from 56-230 minutes. Blood loss ranged from 50-250 ml. All patients were discharged before 48 hours after the end of the surgery. Five-year OS and DFS were 100%, and 94%, respectively. Median time was 125 minutes for Group 1 and 63 minutes for Group 2 (p=0.0002). Following the principles of oncologic safety and in the hands of experienced surgeons, laparoscopy is safe, feasible and effective in the treatment of stage I endometrial cancer.

Keywords:

Endometrial cancer; Laparoscopy; Uterine manipulator

Citation:

Gomes-Da-Silveira GG, Nervo CC, Pontremoli Salcedo M, El Beitune P. Total Laparoscopic Treatment of Endometrial Cancer – Pilot Study with a New Model of Uterine Manipulator: Operating Data and Five Years Follow-up in a Reference Center in Southern Brazil. J Clin Obstet Gynecol Infertil. 2016; 1(1): 1002.

Subscribe to Our Newsletter